LLLawrence L. K. Leung

Lawrence L. K. Leung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lawrence L. K. Leung has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • John Morser

    Division of Hematology, Stanford University School of Medicine, Stanford, California, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA

    12 shared publications
  • Timothy Myles

    Division of Hematology, Stanford University School of Medicine, Stanford, California, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA

    7 shared publications
  • Lei Zhao

    Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA

    6 shared publications
  • Lei Zhao

    Division of Hematology, Stanford University School of Medicine, Stanford, California, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA

    4 shared publications
  • Xiao-Yan Du

    The §Medical Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304

    4 shared publications
  • Jason J. Song

    The ‡‡Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94305

    3 shared publications

Latest Publications

  • Open Access

    Active Forms of Chemerin Are Elevated in Human and Mouse Ovarian Carcinoma

    by Lei Zhao, Qin Zhou, Venkatesh Krishnan, Justine Chan, Simone Sasse, Supreeti Tallapragada, Dan Eisenberg, Lawrence Leung, Oliver Dorigo, John Morser

    Background: Chemerin is a small adipokine that is activated and inactivated by proteolysis of its C-terminus with a role in regulating metabolism, immunity, and inflammation. Significant levels of chemerin are found in circulation and ascitic fluid of ovarian carcinoma patients. Methods: We investigated the levels of different chemerin forms in three cohorts: people with BMI < 25, with BMI > 40, and ovarian carcinoma ascites with ELISAs specific for different chemerin forms. Ascites from a mouse model of ovarian carcinoma were also analyzed, and the model was compared between wild-type and chemerin-deficient mice. Results: Conversion of plasma to serum increased the levels of processed chemerin with lower increases in samples from people with BMI < 25 than in people with BMI > 40. High levels of total chemerin and processed forms of chemerin were found in ascitic fluid from both patients who had a mean BMI of 29 and the mouse model. In chemerin-deficient mice the tumors grew slower than in wild-type mice. Conclusions: Serum has more processed and active chemerin than plasma irrespective of source. Ascites of ovarian carcinoma patients contained high levels of active chemerin, which, based on the mouse data, enhance tumor growth.


  • Open Access

    Chemerin Levels in Individuals with Type 2 Diabetes and a Normal Weight versus Individuals with Type 2 Diabetes and Obesity: An Observational, Cross-Sectional Study

    by Aishee B. Mukherji, Victoria Idowu, Lei Zhao, Lawrence L. K. Leung, Sa Shen, Latha Palaniappan, John Morser

    Chemerin acts as both a chemotactic agent and an adipokine that undergoes proteolytic cleavage, converting inactive precursors into their active forms before being subsequently inactivated. Elevated chemerin levels are linked to obesity and type 2 diabetes mellitus (T2D). This study aimed to elucidate the effects of T2D and obesity on chemerin levels by comparing plasma samples from individuals with a normal weight and T2D (BMI < 25; NWD group n = 22) with those from individuals who are overweight or obese and have T2D (BMI ≥ 25; OWD group n = 39). The total chemerin levels were similar in the NWD and OWD groups, suggesting that T2D may equalize the chemerin levels irrespective of obesity status. The cleavage of chemerin has been previously linked to myocardial infarction and stroke in NWD, with potential implications for inflammation and mortality. OWD plasma exhibited lower levels of cleaved chemerin than the NWD group, suggesting less inflammation in the OWD group. Here, we showed that the interaction between obesity and T2D leads to an equalization in the total chemerin levels. The cleaved chemerin levels and the associated inflammatory state, however, differ significantly, underscoring the complex relationship between chemerin, T2D, and obesity.


  • Open Access

    Chemerin in Participants with or without Insulin Resistance and Diabetes

    by Lei Zhao, Jonathan Zhou, Fahim Abbasi, Mohsen Fathzadeh, Joshua W. Knowles, Lawrence L. K. Leung, John Morser

    Chemerin is a chemokine/adipokine, regulating inflammation, adipogenesis and energy metabolism whose activity depends on successive proteolytic cleavages at its C-terminus. Chemerin levels and processing are correlated with insulin resistance. We hypothesized that chemerin processing would be higher in individuals with type 2 diabetes (T2D) and in those who are insulin resistant (IR). This hypothesis was tested by characterizing different chemerin forms by specific ELISA in the plasma of 18 participants with T2D and 116 without T2D who also had their insulin resistance measured by steady-state plasma glucose (SSPG) concentration during an insulin suppression test. This approach enabled us to analyze the association of chemerin levels with a direct measure of insulin resistance (SSPG concentration). Participants were divided into groups based on their degree of insulin resistance using SSPG concentration tertiles: insulin sensitive (IS, SSPG ≤ 91 mg/dL), intermediate IR (IM, SSPG 92–199 mg/dL), and IR (SSPG ≥ 200 mg/dL). Levels of different chemerin forms were highest in patients with T2D, second highest in individuals without T2D who were IR, and lowest in persons without T2D who were IM or IS. In the whole group, chemerin levels positively correlated with both degree of insulin resistance (SSPG concentration) and adiposity (BMI). Participants with T2D and those without T2D who were IR had the most proteolytic processing of chemerin, resulting in higher levels of both cleaved and degraded chemerin. This suggests that increased inflammation in individuals who have T2D or are IR causes more chemerin processing.


  • Methods to Investigate Thrombin Cleavage of Osteopontin (OPN)

    by Lei Zhao, Lawrence L. Leung, John Morser

    Osteopontin (OPN) is a matricellular protein containing binding sites for a variety of ligands including an RGD sequence for binding to αvβ3 integrins. OPN is a conserved substrate for thrombin, the effector protease of the coagulation cascade. Thrombin cleaves OPN at a single site revealing new functionalities such as a previously cryptic α4β1 and α9β1 integrin-binding site. That integrin-binding site is abolished upon treatment with a basic carboxypeptidase. The thrombin cleavage of OPN has been demonstrated to play a role in regulating tumor growth. This report describes methods for production of full-length OPN as well as the enzymatically cleaved OPN fragments resulting from thrombin and carboxypeptidase treatments. Quantification procedures for the various OPN proteins are described as well as functional assays on mouse melanoma and myeloid cell lines. Key words ELISA Integrins Melanoma Macrophage Osteopontin thrombin Western blot


  • Open Access

    Thrombin Cleavage of Osteopontin and the Host Anti-Tumor Immune Response

    by Lawrence L. Leung, Timothy Myles, John Morser

    Osteopontin (OPN) is a multi-functional protein that is involved in various cellular processes such as cell adhesion, migration, and signaling. There is a single conserved thrombin cleavage site in OPN that, when cleaved, yields two fragments with different properties from full-length OPN. In cancer, OPN has tumor-promoting activity and plays a role in tumor growth and metastasis. High levels of OPN expression in cancer cells and tumor tissue are found in various types of cancer, including breast, lung, prostate, ovarian, colorectal, and pancreatic cancer, and are associated with poor prognosis and decreased survival rates. OPN promotes tumor progression and invasion by stimulating cell proliferation and angiogenesis and also facilitates the metastasis of cancer cells to other parts of the body by promoting cell adhesion and migration. Furthermore, OPN contributes to immune evasion by inhibiting the activity of immune cells. Thrombin cleavage of OPN initiates OPN’s tumor-promoting activity, and thrombin cleavage fragments of OPN down-regulate the host immune anti-tumor response.


  • Open Access

    Chemerin Forms: Their Generation and Activity

    by Lei Zhao, Lawrence L. Leung, John Morser

    Chemerin is the product of the RARRES2 gene which is secreted as a precursor of 143 amino acids. That precursor is inactive, but proteases from the coagulation and fibrinolytic cascades, as well as from inflammatory reactions, process the C-terminus of chemerin to first activate it and then subsequently inactivate it. Chemerin can signal via two G protein-coupled receptors, chem1 and chem2, as well as be bound to a third non-signaling receptor, CCRL2. Chemerin is produced by the liver and secreted into the circulation as a precursor, but it is also expressed in some tissues where it can be activated locally. This review discusses the specific tissue expression of the components of the chemerin system, and the role of different proteases in regulating the activation and inactivation of chemerin. Methods of identifying and determining the levels of different chemerin forms in both mass and activity assays are reviewed. The levels of chemerin in circulation are correlated with certain disease conditions, such as patients with obesity or diabetes, leading to the possibility of using chemerin as a biomarker.


  • Thrombin cleavage of osteopontin initiates osteopontin’s tumor‐promoting activity

    by Sameera Peraramelli, Qi Zhou, Qin Zhou, Bettina Wanko, Lei Zhao, Toshihiko Nishimura, Thomas H. Leung, Seiya Mizuno, Mamoru Ito, Timothy Myles, et al.


  • Open Access

    Chemerin 156F, generated by chymase cleavage of prochemerin, is elevated in joint fluids of arthritis patients

    by Lei Zhao, Yasuto Yamaguchi, Xiaomei Ge, William H. Robinson, John Morser, Lawrence L. K. Leung

    Chemerin is a chemoattractant involved in immunity that also functions as an adipokine. Chemerin is secreted as an inactive precursor (chem163S), and its activation requires proteolytic cleavages at its C-terminus, involving proteases in coagulation, fibrinolysis, and inflammation. Previously, we found chem158K was the dominant chemerin form in synovial fluids from patients with arthritis. In this study, we aimed to characterize a distinct cleaved chemerin form, chem156F, in osteoarthritis (OA) and rheumatoid arthritis (RA). Purified chem156F was produced in transfected CHO cells. To quantify chem156F in OA and RA samples, we developed a specific ELISA for chem156F using antibody raised against a peptide representing the C-terminus of chem156F. Ca2+ mobilization assays showed that the EC50 values for chem163S, chem156F, and chem157S were 252 ± 141 nM, 133 ± 41.5 nM, and 5.83 ± 2.48 nM, respectively. chem156F was more active than its precursor, chem163S, but very much less potent than chem157S, the most active chemerin form. Chymase was shown to be capable of cleaving chem163S at a relevant rate. Using the chem156F ELISA we found a substantial amount of chem156F present in synovial fluids from patients with OA and RA, 24.06 ± 5.51 ng/ml and 20.35 ± 5.19 ng/ml (mean ± SEM, n = 25) respectively, representing 20% of total chemerin in OA and 76.7% of chemerin in RA synovial fluids. Our data show that chymase cleavage of chem163S to partially active chem156F can be found in synovial fluids where it can play a role in modulation of the inflammation in joints.